|
Real-time Estimate
Cboe BZX
19:42:25 19/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 225.96 USD | +3.64% |
|
+6.22% | +669.91% |
| 05:55pm | Oddo BHF Adjusts Moderna Price Target to $251 From $170 | MT |
| 10-16 | Moderna Insider Sold Shares Worth $17,013,538, According to a Recent SEC Filing | MT |
| Market Cap | 87.04B 77.59B 71.87B 65.35B 123B 8,252B 125B 862B 339B 4,313B 327B 320B 13,787B | P/E 2026 * |
-26x | P/E 2027 * | -45.6x |
|---|---|---|---|---|---|
| Enterprise Value | 83.12B 74.1B 68.64B 62.41B 117B 7,881B 119B 823B 324B 4,119B 312B 305B 13,168B | EV / Sales 2026 * |
39.6x | EV / Sales 2027 * | 34.7x |
| Free-Float |
92.66% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Tradegate
| 0QF | Real-time | |
|
Xetra
| 0QF | Delayed | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
CBOE
| Real-time | ||
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Boerse Muenchen
| 0QF | Real-time | |
|
CBOE
| 0A45 | Real-time | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
London S.E.
| 0A45 | Delayed | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed | |
|
Lima
| MRNAUS | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript: Moderna, Inc.
| 1 day | +2.33% | ||
| 1 week | +4.08% | ||
| Current month | +15.52% | ||
| 1 month | +28.63% | ||
| 3 months | +273.94% | ||
| 6 months | +307.51% | ||
| Current year | +654.35% |
| 1 week | 204.7 |  | 242.29 |
| 1 month | 159.06 | | 242.29 |
| Current year | 29.81 | | 242.29 |
| 1 year | 22.28 | | 242.29 |
| 3 years | 22.28 | | 242.29 |
| 5 years | 22.28 | | 376.65 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 10/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/10/26 | Exercice | Chairperson | 192,049 | 0.0481% | ||
| 05/10/26 | Other | Chief Operating Officer | 125,000 | 0.0313% | ||
| 05/10/26 | Exercice | Chief Financial Officer | 3,612 | 0.0009% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.30% | +4.08% | +716.66% | +170.07% | 87.04B | |
| -0.61% | +5.60% | +54.37% | +111.38% | 1,120B | |
| -0.70% | -3.82% | +30.94% | +66.53% | 616B | |
| -0.48% | +1.00% | +22.36% | +95.12% | 504B | |
| +0.24% | +5.58% | +35.22% | +59.40% | 367B | |
| -0.98% | -0.64% | +67.43% | +43.91% | 360B | |
| -0.40% | +3.53% | +19.26% | +46.55% | 288B | |
| -0.37% | +3.11% | -1.31% | +18.23% | 258B | |
| -1.07% | +2.54% | +41.16% | +52.60% | 234B | |
| -1.04% | +2.75% | +25.55% | +97.06% | 194B | |
| Average | -0.32% | +2.67% | +101.17% | +76.08% | 402.79B | |
| Weighted average by Cap. | -0.53% | +3.38% | +52.29% | +78.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.87B 1.74B 1.58B 2.96B 199B 3.01B 20.81B 8.18B 104B 7.88B 7.72B 333B | 2.44B 2.17B 2.01B 1.83B 3.44B 231B 3.49B 24.15B 9.5B 121B 9.15B 8.96B 386B |
| Net income | -3.36B -2.99B -2.77B -2.52B -4.73B -318B -4.81B -33.25B -13.07B -166B -12.6B -12.33B -532B | -1.91B -1.71B -1.58B -1.44B -2.7B -181B -2.74B -18.95B -7.45B -94.83B -7.18B -7.03B -303B |
| Net Debt | -3.91B -3.49B -3.23B -2.94B -5.51B -371B -5.6B -38.76B -15.24B -194B -14.68B -14.37B -620B | -2.44B -2.18B -2.02B -1.83B -3.44B -232B -3.5B -24.21B -9.52B -121B -9.17B -8.98B -387B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/10/26 | US$226.35 | +3.82% | 13,760,997 |
| 16/10/26 | US$218.01 | -7.82% | 21,403,317 |
| 15/10/26 | US$236.50 | +4.51% | 17,313,520 |
| 14/10/26 | US$226.30 | +4.65% | 16,625,367 |
| 13/10/26 | US$216.25 | +1.17% | 13,389,287 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
